u/stockratic

2 theses · first seen Aug 21, 2026

Window	Theses	Resolved	Win rate	Avg return	Median return
1d	0	0	—	—	—
3d	1	1	0%	-3.1%	-3.1%
1w	1	1	0%	-0.3%	-0.3%
1m	0	0	—	—	—
3m	0	0	—	—	—
6m	0	0	—	—	—
1y	0	0	—	—	—

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$CYCUr/pennystocksDDbullish

u/stockratic · 7h ago1 prior · awaiting results

CYCURION (CYCU) - This data clearly indicates the substantial risk being taken by those betting against this company that continues to announce wins and is UNDERVALUED. Next week is shaping up to have great potential!

CYCU is undervalued and has announced multiple notable wins recently. High short-sale volume (reaching 62%) suggests shorts are taking substantial risk, creating potential catalyst for share price recovery next week.

original post →

$NRXPr/pennystocksDDbullish

u/stockratic · 14d ago1 prior · awaiting results

NRx Pharmaceuticals (NRXP) - Awaiting ANDA (generic drug) approval for no-preservative Intravenous (IV) ketamine for analgesia (pain control) and anesthesia ... which will happen in the near term.

NRx Pharmaceuticals is positioned for near-term FDA approval of KETAFREE (preservative-free ketamine), addressing critical supply chain and safety issues while solving strategic FDA goals. The company has resolved the only outstanding FDA concern (luer lock vial attestation) and has significant pre-launch commercialization momentum, with share price expected to respond positively to ANDA approval and subsequent NDA filings.

At post $3.56Now $3.49-2.0% since postedas of Sep 4, 4:30 PM ET

1d—

3d-3.1%

1w-0.3%

1m—

3m—

6m—

1y—

original post →

End of results.